Novartis' Del-Desiran Misses Primary Endpoint In Phase 3 DM1 Study; Stock Down 12%

Novartis reported that its Phase 3 HARBOR trial of del-desiran in myotonic dystrophy type 1 failed to meet the primary endpoint of video hand opening time (vHOT). The failed late-stage study is a material setback for the program and could pressure Novartis shares, though the article provides no additional efficacy, safety, or financial details.